Medikaloka Hermina Tbk PT
IDX:HEAL

Watchlist Manager
Medikaloka Hermina Tbk PT Logo
Medikaloka Hermina Tbk PT
IDX:HEAL
Watchlist
Price: 1 460 IDR 0.69% Market Closed
Market Cap: 21.6T IDR
Have any thoughts about
Medikaloka Hermina Tbk PT?
Write Note

Intrinsic Value

The intrinsic value of one HEAL stock under the Base Case scenario is 1 277.4 IDR. Compared to the current market price of 1 460 IDR, Medikaloka Hermina Tbk PT is Overvalued by 13%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

HEAL Intrinsic Value
1 277.4 IDR
Overvaluation 13%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Medikaloka Hermina Tbk PT

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for HEAL cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about HEAL?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Health Care Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Medikaloka Hermina Tbk PT

Provide an overview of the primary business activities
of Medikaloka Hermina Tbk PT.

What unique competitive advantages
does Medikaloka Hermina Tbk PT hold over its rivals?

What risks and challenges
does Medikaloka Hermina Tbk PT face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Medikaloka Hermina Tbk PT.

Provide P/S
for Medikaloka Hermina Tbk PT.

Provide P/E
for Medikaloka Hermina Tbk PT.

Provide P/OCF
for Medikaloka Hermina Tbk PT.

Provide P/FCFE
for Medikaloka Hermina Tbk PT.

Provide P/B
for Medikaloka Hermina Tbk PT.

Provide EV/S
for Medikaloka Hermina Tbk PT.

Provide EV/GP
for Medikaloka Hermina Tbk PT.

Provide EV/EBITDA
for Medikaloka Hermina Tbk PT.

Provide EV/EBIT
for Medikaloka Hermina Tbk PT.

Provide EV/OCF
for Medikaloka Hermina Tbk PT.

Provide EV/FCFF
for Medikaloka Hermina Tbk PT.

Provide EV/IC
for Medikaloka Hermina Tbk PT.

Show me price targets
for Medikaloka Hermina Tbk PT made by professional analysts.

What are the Revenue projections
for Medikaloka Hermina Tbk PT?

How accurate were the past Revenue estimates
for Medikaloka Hermina Tbk PT?

What are the Net Income projections
for Medikaloka Hermina Tbk PT?

How accurate were the past Net Income estimates
for Medikaloka Hermina Tbk PT?

What are the EPS projections
for Medikaloka Hermina Tbk PT?

How accurate were the past EPS estimates
for Medikaloka Hermina Tbk PT?

What are the EBIT projections
for Medikaloka Hermina Tbk PT?

How accurate were the past EBIT estimates
for Medikaloka Hermina Tbk PT?

Compare the revenue forecasts
for Medikaloka Hermina Tbk PT with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Medikaloka Hermina Tbk PT and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Medikaloka Hermina Tbk PT against its competitors.

Analyze the profit margins
(gross, operating, and net) of Medikaloka Hermina Tbk PT compared to its peers.

Compare the P/E ratios
of Medikaloka Hermina Tbk PT against its peers.

Discuss the investment returns and shareholder value creation
comparing Medikaloka Hermina Tbk PT with its peers.

Analyze the financial leverage
of Medikaloka Hermina Tbk PT compared to its main competitors.

Show all profitability ratios
for Medikaloka Hermina Tbk PT.

Provide ROE
for Medikaloka Hermina Tbk PT.

Provide ROA
for Medikaloka Hermina Tbk PT.

Provide ROIC
for Medikaloka Hermina Tbk PT.

Provide ROCE
for Medikaloka Hermina Tbk PT.

Provide Gross Margin
for Medikaloka Hermina Tbk PT.

Provide Operating Margin
for Medikaloka Hermina Tbk PT.

Provide Net Margin
for Medikaloka Hermina Tbk PT.

Provide FCF Margin
for Medikaloka Hermina Tbk PT.

Show all solvency ratios
for Medikaloka Hermina Tbk PT.

Provide D/E Ratio
for Medikaloka Hermina Tbk PT.

Provide D/A Ratio
for Medikaloka Hermina Tbk PT.

Provide Interest Coverage Ratio
for Medikaloka Hermina Tbk PT.

Provide Altman Z-Score Ratio
for Medikaloka Hermina Tbk PT.

Provide Quick Ratio
for Medikaloka Hermina Tbk PT.

Provide Current Ratio
for Medikaloka Hermina Tbk PT.

Provide Cash Ratio
for Medikaloka Hermina Tbk PT.

What is the historical Revenue growth
over the last 5 years for Medikaloka Hermina Tbk PT?

What is the historical Net Income growth
over the last 5 years for Medikaloka Hermina Tbk PT?

What is the current Free Cash Flow
of Medikaloka Hermina Tbk PT?

Discuss the annual earnings per share (EPS)
trend over the past five years for Medikaloka Hermina Tbk PT.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Medikaloka Hermina Tbk PT

Current Assets 2.2T
Cash & Short-Term Investments 949.8B
Receivables 1.1T
Other Current Assets 131.8B
Non-Current Assets 7.7T
PP&E 7.3T
Other Non-Current Assets 326.5B
Current Liabilities 1.5T
Accounts Payable 350.8B
Accrued Liabilities 129B
Short-Term Debt 67.7B
Other Current Liabilities 988.2B
Non-Current Liabilities 4.1T
Long-Term Debt 2.6T
Other Non-Current Liabilities 1.5T
Efficiency

Earnings Waterfall
Medikaloka Hermina Tbk PT

Revenue
6.4T IDR
Cost of Revenue
-4T IDR
Gross Profit
2.4T IDR
Operating Expenses
-1.3T IDR
Operating Income
1.1T IDR
Other Expenses
-486.6B IDR
Net Income
578.2B IDR

Free Cash Flow Analysis
Medikaloka Hermina Tbk PT

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

HEAL Profitability Score
Profitability Due Diligence

Medikaloka Hermina Tbk PT's profitability score is 54/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive 3-Year Average ROE
Positive Operating Income
Positive Revenue Growth Forecast
54/100
Profitability
Score

Medikaloka Hermina Tbk PT's profitability score is 54/100. The higher the profitability score, the more profitable the company is.

HEAL Solvency Score
Solvency Due Diligence

Medikaloka Hermina Tbk PT's solvency score is 45/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Low D/E
Long-Term Solvency
Short-Term Solvency
45/100
Solvency
Score

Medikaloka Hermina Tbk PT's solvency score is 45/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

HEAL Price Targets Summary
Medikaloka Hermina Tbk PT

Wall Street analysts forecast HEAL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for HEAL is 1 799.28 IDR with a low forecast of 1 424.1 IDR and a high forecast of 2 100 IDR.

Lowest
Price Target
1 424.1 IDR
2% Downside
Average
Price Target
1 799.28 IDR
23% Upside
Highest
Price Target
2 100 IDR
44% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for HEAL?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for HEAL is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Medikaloka Hermina Tbk PT Logo
Medikaloka Hermina Tbk PT

Country

Indonesia

Industry

Health Care

Market Cap

21.7T IDR

Dividend Yield

0.58%

Description

PT Medikaloka Hermina engages in healthcare services. The company is headquartered in Jakarta Timur, Dki Jakarta and currently employs 15,086 full-time employees. The company went IPO on 2018-05-16. The firm is focused on providing services for BPJS patients to support government program in Indonesia. The Company’s services include hospitals, specialties and featured services. The Company’s hospitals include Hermina Arcamanik, Hermina Balikpapan, Hermina Banyumanik, Hermina Bekasi, Hermina Bitung, Hermina Bogor, Hermina Ciledug, Hermina Cilegon and Hermina Ciputat. In specialties service, the Company provides anatomical pathology, andrology, anesthesiology, cardiology, clinical microbiology, clinical pathology, dentistry, dermatology and venereology, dietetics, emergency medicine, forensic and medicolegal, internal medicine, medical acupuncture, neurology and surgery. The Company’s subsidiaries include PT Medikaloka Internusa (M Internusa), PT Medikaloka Sejahtera (M Sejahtera), PT Medikaloka Husada (M Husada), PT Medikaloka Daan Mogot and PT Medikaloka Pasteur (M Pasteur).

Contact

DKI JAKARTA
Jakarta Timur
Jalan Raya Jatinegara Barat No. 126
+62218572525
www.herminahospitals.com

IPO

2018-05-16

Employees

15 086

Officers

See Also

Discover More
What is the Intrinsic Value of one HEAL stock?

The intrinsic value of one HEAL stock under the Base Case scenario is 1 277.4 IDR.

Is HEAL stock undervalued or overvalued?

Compared to the current market price of 1 460 IDR, Medikaloka Hermina Tbk PT is Overvalued by 13%.

Back to Top